| Project/Area Number |
26462182
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
安原 隆雄 岡山大学, 医歯薬学総合研究科, 講師 (50457214)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
DATE Isao 岡山大学, 医歯薬学総合研究科, 教授 (70236785)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | Oncolytic virus / stem cell / antiangiogenesis / glioma / molecular targeted drug / antiinvasion |
|---|
| Outline of Final Research Achievements |
Oncolytic viral (OV) therapy has been considered as a promising treatment modality for brain tumors. Previously a novel HSV-1 derived OV, 34.5ENVE (viral ICP34.5 Expressed by Nestin promotor and Vstat120 Expressing), was reported to have a potent antitumor effect. Here, we investigated the therapeutic efficacy of 34.5ENVE and cilengitide, an integrin inhibitor, or, bevacizumab, an VEGF antibody combination therapy for malignant glioma. Before the experiment of the combination with 34.5ENVE and targeted drug we evaluated the combination therapy with a first generation OV armed with the antiangiogenic gene Vstat120 (RAMBO). In the scratch wound assay, RAMBO CM significantly reduced both the number of migrating cells and the rate of migration. Furthermore, the number and the rate of migrating cells induced by bevacizumab treatment was reduced by RAMBO CM. These results indicate that targeted drug enhanced OV therapy for malignant glioma.
|
